List of Excipients in Branded Drug PRANDIN

Generic Drugs Containing PRANDIN

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals LLC	repaglinide	60846-882	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
Amneal Pharmaceuticals LLC	repaglinide	60846-882	CELLULOSE, MICROCRYSTALLINE
Amneal Pharmaceuticals LLC	repaglinide	60846-882	CROSCARMELLOSE SODIUM
Amneal Pharmaceuticals LLC	repaglinide	60846-882	FERRIC OXIDE YELLOW

What are the Most Frequently-Used Excipients in PRANDIN?

# Of NDCs	Excipient
1	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	FERRIC OXIDE YELLOW

PRANDIN Excipient Strategy and Commercial Opportunities for Repaglinide

Last updated: August 29, 2026

Prandin is the brand name for repaglinide, an oral meglitinide used to lower postprandial blood glucose in adults with type 2 diabetes. Its commercial opportunity is primarily generic and reformulation-driven. The legacy immediate-release tablet has a simple excipient platform, low dose strength, established FDA approval, and no meaningful biosimilar barrier. The strongest opportunities are low-cost generic supply, improved dissolution, orally disintegrating tablets, fixed-dose combinations, and differentiated products for patients who need flexible meal-time dosing.

Prandin’s core composition is no longer a strong exclusivity platform. The historical U.S. composition patent expired in 2011, with any applicable pediatric extension ending in 2012. Current commercial value depends on manufacturing efficiency, regulatory execution, product differentiation, and access to diabetes channels rather than brand patent protection.

What is Prandin and how is repaglinide formulated?

Prandin contains repaglinide, a short-acting insulin secretagogue that stimulates pancreatic insulin release. The FDA-approved product is taken before meals, with dosing adjusted according to meal timing and glycemic response. The labeled strengths are 0.5 mg, 1 mg, and 2 mg tablets. The maximum recommended daily dose is 16 mg.[1]

The immediate-release tablet uses conventional solid-dose excipients. The FDA label identifies the principal inactive ingredients as:

Excipient category	Prandin ingredient or function	Commercial relevance
Diluent and compression aid	Calcium hydrogen phosphate, cellulose	Supports tablet weight and mechanical strength
Solubilizing or wetting component	Meglumine	Can improve microenvironmental solubility
Superdisintegrant or swelling polymer	Polacrilin potassium	Supports tablet breakup and drug release
Binder	Povidone	Improves granule and tablet cohesion
Disintegrant or filler	Starch	Supports disintegration and processing
Lubricant	Magnesium stearate	Reduces tooling friction
Colorants	Strength-specific coloring agents	Supports dose differentiation and identification

The exact excipient profile, colorant system, and manufacturing process must be confirmed against the current reference-product labeling and FDA inactive-ingredient records before an ANDA or reformulation program is finalized.[1,2]

What excipients are protected by Prandin patents?

The legacy Prandin product did not create a durable commercial barrier around its ordinary tablet excipients. Generic manufacturers can generally use different inactive ingredients if the finished product meets the applicable requirements for pharmaceutical equivalence, bioequivalence, quality, and labeling.

The most commercially relevant historical U.S. patent was U.S. Patent No. 5,312,924, which covered repaglinide-related pharmaceutical subject matter and expired in 2011. A pediatric exclusivity extension, where applicable, extended the effective protection into 2012. Other historical patents and method-of-use rights may have covered repaglinide products or diabetes treatment methods, but these dates do not create a current barrier to ordinary repaglinide tablet development.[3]

Are Prandin excipients independently patentable?

An excipient combination could support a new patent only if the claimed formulation has the required novelty, non-obviousness, utility, and enabling disclosure. A generic copy using calcium hydrogen phosphate, cellulose, meglumine, polacrilin potassium, povidone, starch, and magnesium stearate would not obtain meaningful exclusivity merely by reproducing the known composition.

Potentially patentable subject matter could include:

• A defined solid dispersion or amorphous repaglinide system.
• A substantially improved dissolution profile.
• A taste-masked orally disintegrating tablet.
• A modified-release system that changes exposure or dosing convenience.
• A stabilized formulation with longer shelf life.
• A low-dose combination product with improved content uniformity.
• A manufacturing process that produces a distinctive polymorph or particle-size distribution.

A formulation patent would need to claim a real technical distinction. Substituting one common filler for another generally offers weak patent protection.

How strong is the current Prandin patent estate?

The current patent estate is commercially weak for conventional repaglinide tablets. The principal risks are regulatory and commercial rather than blocking patent claims.

Issue	Assessment
Core compound protection	Historical protection expired
Conventional tablet formulation	Low protection value
Method-of-use patents	Historical rights may exist, but do not generally block broad generic tablet entry after expiry
Orange Book strategy	Limited relevance once listed patents expire
Formulation opportunity	Available if supported by new technical performance
Biosimilar risk	Not applicable; repaglinide is a small molecule
Generic risk	High
Manufacturing barrier	Moderate only if process capability, impurity control, or API access is difficult

The strongest defensible position for a new entrant would come from a differentiated formulation or combination product, not from the existing Prandin excipient set.

What is the FDA and Orange Book status of Prandin?

Prandin was approved by the FDA under NDA 020741. Repaglinide is also available through generic abbreviated new drug applications. FDA approval of generic repaglinide tablets is based on pharmaceutical equivalence and bioequivalence to the reference listed drug, subject to applicable ANDA requirements.[1,4]

The Orange Book remains relevant for:

• Identifying the reference listed drug.
• Reviewing any remaining patent or exclusivity entries.
• Confirming dosage forms and strengths.
• Assessing therapeutic-equivalence designations.
• Tracking discontinued or commercially unavailable reference products.

The central regulatory point is that an applicant pursuing a conventional immediate-release generic does not need to reproduce the Prandin excipient formula. It must demonstrate that the proposed product meets the relevant quality and bioequivalence standards.

Does Prandin have new chemical entity exclusivity?

No current new chemical entity exclusivity should be expected for repaglinide. The product was approved decades ago, and the commercial opportunity is now based on generic approval, formulation development, or a new combination or delivery system.

What excipient strategy is best for a generic repaglinide tablet?

The lowest-risk strategy is a conventional immediate-release tablet that uses widely accepted excipients and closely matches the reference product’s performance.

A practical formulation platform would prioritize:

1. Consistent low-dose content uniformity.
2. Rapid disintegration and dissolution.
3. Low moisture sensitivity.
4. Robust compression at the 0.5 mg strength.
5. Simple, scalable granulation or direct-compression processing.
6. Minimal excipient-related food or absorption effects.
7. Strong stability under commercial packaging conditions.

Repaglinide is administered at a very low dose. That creates a content-uniformity challenge, particularly for the 0.5 mg tablet. A high-quality manufacturing process may be more valuable than an aggressive excipient innovation program.

What excipients can improve repaglinide dissolution?

Repaglinide is commonly characterized as a poorly water-soluble, highly permeable compound. Candidate approaches include:

• Meglumine or other pH-modifying agents.
• Poloxamers or other surfactants.
• Cyclodextrin complexes.
• Spray-dried amorphous solid dispersions.
• Nanosized drug particles.
• Lipid-based systems.
• Porous carriers or co-processing excipients.

The commercial value of these approaches depends on whether they improve clinically relevant exposure, reduce variability, or produce a measurable manufacturing advantage. A faster dissolution result alone may not support premium pricing if the conventional generic already meets bioequivalence requirements.

What formulation patents could create commercial differentiation?

Orally disintegrating repaglinide tablets

An orally disintegrating tablet could target patients who have difficulty swallowing or need a convenient pre-meal dosage form. Suitable excipient systems may include mannitol, microcrystalline cellulose, crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, and taste-masking agents.

The principal development risks are:

• Bitter or metallic taste from repaglinide.
• Dose uniformity at low drug load.
• Friability during packaging and distribution.
• Moisture sensitivity.
• Demonstrating bioequivalence to an immediate-release tablet.
• Establishing appropriate labeling for administration before meals.

Taste masking may require polymer coating, ion-exchange resin complexation, cyclodextrin inclusion, or flavor systems. A taste-masked product could support a 505(b)(2) strategy or a differentiated generic pathway, depending on the final dosage form and regulatory claims.

Modified-release repaglinide

Modified release could reduce repeated meal-time dosing, but the clinical rationale is less straightforward than for longer-acting diabetes medicines. Repaglinide’s short action is linked to its pre-meal use and lower risk of prolonged insulin stimulation relative to longer-acting secretagogues.

Potential technologies include hydrophilic matrices, multiparticulates, coated pellets, osmotic systems, and gastroretentive platforms. These products would face higher development costs and more complex clinical and pharmacokinetic requirements. The commercial case would need to show improved adherence, reduced dosing burden, or a meaningful safety advantage.

Fixed-dose combinations

A repaglinide-metformin product is the most obvious combination opportunity because the agents have complementary mechanisms and have been used together clinically. Commercial development would need to address:

• Dose flexibility for each component.
• Meal-related administration.
• Tablet size.
• Stability of both actives.
• Different titration requirements.
• Bioequivalence for each component.
• Labeling and contraindications associated with metformin.

A fixed-dose product could compete in markets where repaglinide remains used for patients requiring flexible prandial treatment. Its value would depend heavily on reimbursement and prescriber acceptance because metformin is inexpensive and widely available.

What generic entry risks exist for Prandin?

Generic entry risk is high because the active ingredient is old, the dosage form is conventional, and core patent protection has expired.

Paragraph IV challenges

A Paragraph IV certification would be relevant only if an applicant were addressing an unexpired Orange Book patent. For conventional repaglinide tablets, historical core patent expiry removes the principal basis for a blocking Paragraph IV dispute.

The more likely regulatory pathway is a Paragraph III certification for any remaining but not yet expired patent, or a Paragraph I certification if no relevant patent is listed. Current certification outcomes must be verified through the active Orange Book entry and the applicant’s ANDA record.[4]

Litigation status and settlement agreements

There is no broad, current patent barrier comparable to the litigation environments surrounding high-revenue protected products. Historical patent disputes may have affected early generic timing, but the present market is primarily shaped by multiple generic manufacturers and price competition.

Settlement agreements involving repaglinide would have limited commercial significance unless they imposed a later launch date, supply restriction, or formulation-specific covenant. Such agreements should be assessed from court dockets, FDA records, and company disclosures rather than inferred from the expired core patent.

Which companies are challenging Prandin’s market position?

The principal challengers are generic manufacturers rather than biosimilar developers. Repaglinide tablets have been marketed by multiple generic companies, including manufacturers that supply U.S. retail, institutional, and international markets. Competition is based on:

• Tablet strengths and pack sizes.
• Wholesale acquisition cost.
• Medicaid and payer contracts.
• Supply reliability.
• FDA inspection history.
• API sourcing.
• Ability to support 0.5 mg content uniformity.
• Distribution through diabetes and primary-care channels.

Novo Nordisk retains strong diabetes-market infrastructure, but Prandin is not positioned like the company’s modern GLP-1, insulin, or obesity products. Brand-level revenue is not generally reported as a separate material segment in company financial disclosures, which limits direct revenue modeling for Prandin.[5]

How does Prandin compare with competing diabetes products?

Product class	Main commercial advantage	Prandin position
Metformin	Low cost and broad first-line use	Repaglinide is more meal-flexible but generally less dominant
Sulfonylureas	Low cost and familiarity	Similar low-cost segment with different dosing and hypoglycemia considerations
DPP-4 inhibitors	Oral dosing and tolerability	More expensive, often stronger branded positioning
SGLT2 inhibitors	Cardiovascular and renal outcome claims	Repaglinide lacks comparable outcome-based differentiation
GLP-1 receptor agonists	Weight and glycemic efficacy	Prandin is cheaper and oral but has limited modern differentiation
Insulin	Broad glucose-lowering capacity	Repaglinide is simpler for selected patients but less potent in advanced disease

Prandin’s commercial niche is flexible pre-meal dosing for patients whose meal patterns or postprandial glucose control make a short-acting secretagogue attractive. Its low price is both a market advantage and a barrier to premium reformulation economics.

What geographic opportunities exist for repaglinide products?

The United States offers a mature generic market with limited brand premium. International opportunities may be stronger in markets where:

• Repaglinide remains included in diabetes treatment guidelines.
• Generic competition is less concentrated.
• Local manufacturing receives procurement preference.
• Tablet affordability is a major purchasing factor.
• Flexible meal-time dosing is clinically relevant.

A geographic strategy should distinguish between regulated markets requiring full bioequivalence packages and emerging markets where local registration, pricing, and tender access determine success. Patent expiry in one jurisdiction does not establish freedom to operate in every country. National patent registers and local regulatory databases remain controlling for launch timing.

What manufacturing and intellectual-property barriers remain?

The API is commercially available, but quality and supply-chain risks remain. Key manufacturing controls include:

• API polymorph and particle-size control.
• Low-dose blending uniformity.
• Impurity and degradation-product limits.
• Dissolution across the proposed shelf life.
• Lubrication control to avoid delayed dissolution.
• Moisture management.
• Packaging protection.
• Reliable supply of qualified excipients.

For a differentiated formulation, the manufacturing process can become the principal barrier. Spray drying, nanosizing, multiparticulate coating, or specialized taste masking adds equipment, scale-up, and validation requirements. These barriers can protect margins operationally even when patent protection is limited.

What are the best commercial opportunities for Prandin excipients?

The most credible opportunities rank as follows:

Opportunity	Investment level	Regulatory complexity	Commercial outlook
Conventional generic tablet	Low to moderate	Low	High-volume, low-margin
Improved dissolution tablet	Moderate	Moderate	Useful if it improves robustness or BE
Orally disintegrating tablet	Moderate	Moderate to high	Differentiated niche
Taste-masked pediatric or dysphagia product	Moderate to high	High	Potential specialty opportunity
Repaglinide-metformin combination	High	High	Possible adherence and access value
Modified-release product	High	High	Uncertain clinical demand
Novel lipid or nanosized formulation	High	High	Patentable but commercially speculative

The strongest near-term business case is a cost-efficient generic tablet supported by excellent supply reliability. The strongest higher-margin case is an orally disintegrating or taste-masked product with a defensible formulation patent and a clear target population.

Key Takeaways

• Prandin is repaglinide, an immediate-release oral diabetes medicine approved in 0.5 mg, 1 mg, and 2 mg tablets.
• The legacy product uses conventional excipients, including calcium hydrogen phosphate, cellulose, meglumine, polacrilin potassium, povidone, starch, and magnesium stearate.
• Core U.S. patent protection expired in 2011, with pediatric exclusivity potentially extending protection into 2012.
• Conventional generic entry risk is high, and biosimilar competition is not applicable.
• Low-dose content uniformity and rapid dissolution are the main formulation and manufacturing priorities.
• Orally disintegrating, taste-masked, fixed-dose combination, and modified-release products offer the main differentiation paths.
• A repaglinide-metformin combination has the clearest clinical and commercial logic among potential combination products.
• Revenue exposure from the branded product is difficult to isolate because Prandin is not generally reported as a separate material revenue category.
• Premium pricing requires a technical advantage, a defined patient population, and protection beyond the legacy excipient formula.
• Geographic launch timing must be assessed country by country because patent, regulatory, pricing, and tender conditions differ.

FAQs

Is Prandin still commercially protected by patents?

The historical U.S. core patent protection has expired. Any launch analysis must still review current Orange Book entries and country-specific rights, but conventional repaglinide tablets generally face generic competition.

Can a company copy Prandin’s excipients?

A company can generally use the same inactive ingredients if the product satisfies applicable FDA quality, pharmaceutical-equivalence, bioequivalence, and labeling requirements. The excipient list itself does not create a current commercial monopoly.

Is repaglinide suitable for an orally disintegrating tablet?

Yes. Its low dose makes an orally disintegrating format technically feasible, but taste masking, content uniformity, friability, moisture protection, and bioequivalence would determine development viability.

Could repaglinide support a 505(b)(2) product?

A differentiated dosage form, modified-release product, or combination product could potentially support a 505(b)(2) strategy, depending on the formulation, proposed labeling, and reliance on prior FDA findings. The regulatory route would be product-specific.

What is the most defensible commercial strategy for repaglinide?

The lowest-risk strategy is a reliable, low-cost immediate-release generic. The most defensible premium strategy is a formulation with measurable clinical or administration benefits, supported by formulation and process patents and targeted at patients with swallowing, adherence, or meal-timing needs.

References

1. U.S. Food and Drug Administration. (2019). Prandin (repaglinide) tablets prescribing information.
2. U.S. National Library of Medicine. (n.d.). DailyMed: Prandin and repaglinide tablet labeling.
3. United States Patent and Trademark Office. (1994). U.S. Patent No. 5,312,924.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. Novo Nordisk A/S. (2023). Annual report 2023.